Madrigal Pharmaceuticals (MDGL) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Powered by 
Analysis
Madrigal Pharmaceuticals (MDGL) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 91.31% |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 17.25% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 37.89% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 37.44% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -38.56% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 62.15% |
| 10 | Madrigal Pharmaceuticals | 15.77 Bn | 14.93 Bn | - | 12.67% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.67% |
| Mar 31, 2026 | -6.27% |
| Dec 31, 2025 | 12.05% |
| Sep 30, 2025 | -11.02% |
| Jun 30, 2025 | 15.76% |
| Mar 31, 2025 | -8.39% |
| Dec 31, 2024 | 2.72% |
| Sep 30, 2024 | -19.23% |
| Jun 30, 2024 | -35.08% |
| Mar 31, 2024 | -40.83% |
| Dec 31, 2023 | -23.80% |
| Sep 30, 2023 | -19.43% |
| Jun 30, 2023 | -20.43% |
| Mar 31, 2023 | -28.62% |
| Dec 31, 2022 | -45.76% |
| Sep 30, 2022 | -55.90% |
| Jun 30, 2022 | -53.13% |
| Mar 31, 2022 | -56.24% |
| Dec 31, 2021 | -77.85% |
| Sep 30, 2021 | -94.98% |